Prostaglandin E2 receptor EP2 subtype

Description:

Description
  • Accession: P43116
  • Swissprot: PE2R2_HUMAN
  • Organism: Homo sapiens
  • Gene: PTGER2
  • Target class: GPCR

Drug Relations:

alprostadil
A potent vasodilator agent that increases peripheral blood flow. Bioactivity details MOA
dinoprostone
The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa. Bioactivity details MOA
rioprostil
A synthetic methylprostaglandin E1 analog that reduces gastric acid secretion and enhances the gastric mucus-bicarbonate barrier. It is effective in the therapy of gastric ulcers and gives significant protection against NSAID-induced gastric mucosal damage. The drug also prevents cyclosporin A-induced damage to endocrine and exocrine pancreatic secretions. It shows a low order of acute toxicity and there is no evidence of embryotoxicity, fetotoxicity, teratogenicity, or mutagenicity in animal studies. Bioactivity details MOA
dinoprost
A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions. Bioactivity details MOA
etoricoxib
inhibits cyclooxygenase-2 Bioactivity details MOA
iloprost
An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation. Bioactivity details MOA
indomethacin
A non-steroidal anti-inflammatory agent (NSAID) that inhibits the enzyme cyclooxygenase necessary for the formation of prostaglandins and other autacoids. It also inhibits the motility of polymorphonuclear leukocytes. Bioactivity details MOA
laropiprant
a potent orally active human prostaglandin D(2) receptor 1 antagonist Bioactivity details MOA
mezlocillin
Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections. Bioactivity details MOA
misoprostol
A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties. Bioactivity details MOA
rofecoxib
a sulfonylphenyl furanone; withdrawn out of concern for TOXICITY Bioactivity details MOA
treprostinil
Bioactivity details MOA